FDA Brief

Warning letters Biologics

FDA warning letter to

OsteoLife Biomedical I LLC

Issued Mar 31, 2022Posted May 31, 2022Office of Biological Products Operations – Division I

Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). We haven't summarized this letter yet. Read it on fda.gov.